CPT1A and obesity due to melanocortin 4 receptor deficiency: Several points of evidence suggest that CPT-1 may be a promising target for the development of therapeutic agents against diabetes and obesity; however, a better understanding of metabolic changes following CPT1A manipulation is needed [22].